Colinz Laboratories Fair Value
Colinz Laboratories fair value. Colinz Laboratories (COLINZ) average fair value is ₹426.54 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹73.0 (+484.3%), fair value range ₹33.33–₹1981.45. Explore Colinz Laboratories intrinsic price to estimate fundamental worth using multiple valuation models.
Fair Value Analysis Export
COLINZ Fair Value vs Current Price — Valuation Summary
COLINZ average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Check COLINZ company valuation to track the company's total market size over time.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
COLINZ Fair Value Analysis — Data Sources & Coverage
Colinz Laboratories financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit COLINZ screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
COLINZ vs Healthcare Sector Peers — P/E, P/B & Market Cap
Colinz Laboratories P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Syngene International | SYNGENE | 68.69 | 3.13 | ₹15,000 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.